Article Text

PDF
OP0135 Clinical and therapeutic features of 270 patients with macrophage activation syndrome enrolled in a multinational survey
  1. S. Davì1,
  2. B. Lattanzi1,
  3. E. Demirkaya1,
  4. S. Rosina1,
  5. A. Novelli1,
  6. N. Ruperto1,
  7. A. Martini1,2,
  8. R.Q. Cron3,
  9. A. Ravelli1,2
  10. and International Investigator Consortium for MAS Diagnostic Criteria
  1. 1Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini
  2. 2Università degli Studi di Genova, Genova, Italy
  3. 3Children’s Hospital of Alabama and University of Alabama at Birmingham, Birmingham, United States

Abstract

Background A multinational collaborative effort aimed to develop a new set of criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) has been recently started. The first step of the project, based on a Delphi survey, has been completed (Davì S et al. J Rheumatol 2011;38:764-8). The second step, whose goal is to collect the data of a sizable sample of children with MAS and with potentially “confusable” conditions, is currently under way.

Objectives To describe the demographic, clinical, laboratory, histopathologic, therapeutic and prognostic features of children with MAS collected so far in the data-collection phase of the project.

Methods Investigators who participated in the Delphi survey were asked to enter the information of their patients with MAS collected retrospectively in a web-based database, developed at the coordinating center (the Istituto G. Gaslini of Genoa, Italy).

Results At the 31st of December, 2011, 270 patients with sJIA-associated MAS have been entered in the study website by 76 investigators from 27 countries. 155 (57,4%) patients were females and 115 (42,6%) were males. The age at onset of sJIA ranged from 0.2 to 19,5 years (median 5 years) and the disease duration from onset of sJIA and onset of MAS ranged from 0 to 15,1 years (median 4,1 years). MAS occurred at onset of sJIA in 50 (18,5%) patients. The frequency of the clinical, laboratory and histopathologic features of MAS is reported in the Table. The most frequently reported trigger of MAS was active disease (33%), followed by infection (26,3%) and medication toxicity (7%). 54 (20%) patients were admitted in the ICU. Therapeutic interventions included iv steroids (83,3%), oral steroids (66,3%), cyclosporine (63,7%), other immunosuppressants (8,9%), iv Ig (33,%), etoposide (8,5%), anakinra (7%), and plasma exchange (3,7%). The mortality rate was 8%.

Table 1. Frequency of clinical, laboratory, histopathologic features of 270 patients with MAS

Conclusions Hyperferritinemia, falling platelet count and increased liver enzymes were the most frequently observed laboratory abnormalities. Notably, the frequency of falling leukocyte count was unexpectedly low. Also unexpectedly, liver and spleen enlargement were recorded more frequently than persistent continuous fever. Hemophagocytosis was noticed in around one third of patients who underwent bone marrow aspirate. As expected, corticosteroids and cyclosporine were the most commonly administered medications.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.